Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Macucil-O3 is an oral dietary supplement developed by Martia Laboratories, an Indian pharmaceutical company specializing in ophthalmic care. It is formulated as an antioxidant support product specifically designed for maintaining eye health and potentially managing conditions such as age-related macular degeneration (AMD). The "O3" designation indicates the inclusion of Omega-3 fatty acids, typically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are combined with a blend of carotenoids like lutein and zeaxanthin. These components work synergistically to protect retinal tissues from oxidative stress and blue light damage, supporting overall visual function and structural integrity of the macula.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Macucil-O3.